TcL Pharma and Lonza have signed a development and supply contract for TcL Pharma’s lead drug candidate, a monoclonal antibody that adjusts the immune system for the potential treatment of graft rejections and patients with auto-immune diseases. The long-term service agreement includes strain development using Lonza’s XS Microbial Expression Technologies through to cGMP manufacture of Phase I clinical material. The first phase of the project will involve strain development using Lonza’s E. co...